Caffeine urinary metabolite ratios as markers of enzyme activity: A theoretical assessment

Pharmacogenetics

Volumn 6, Issue 2, 1996, Pages 121-149

  Rostami Hodjegan, A ^a   Nurminen, S ^a   Jackson, P R ^a   Tucker, G T ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

caffeine; CYP1A2; enzyme activity; metabolite ratios; NAT2; urine

Indexed keywords

ACYLTRANSFERASE; CAFFEINE; CYTOCHROME P450 ISOENZYME; DRUG METABOLITE; MARKER; PARAXANTHINE;

ARTICLE; BIOTRANSFORMATION; COMPUTER SIMULATION; CONTROLLED STUDY; DRUG HALF LIFE; DRUG SALIVA LEVEL; DRUG URINE LEVEL; ENZYME ACTIVITY; GENETIC POLYMORPHISM; HUMAN; KINETICS; MICTURITION; PRIORITY JOURNAL; THEORETICAL STUDY; URINARY EXCRETION;

ARYLAMINE N-ACETYLTRANSFERASE; BIOLOGICAL MARKERS; CAFFEINE; COMPUTER SIMULATION; CYTOCHROME P-450 CYP1A2; DATA INTERPRETATION, STATISTICAL; HUMANS; KINETICS; MATHEMATICS; MODELS, BIOLOGICAL; POLYMORPHISM, GENETIC; SALIVA; SENSITIVITY AND SPECIFICITY;

EID: 0029974530     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199604000-00001     Document Type: Article

References (69)

1. Balogh A, Harder S, Vollandt, Staib H. Intra-individual variability of caffeine elimination in healthy subjects. Int J Clin Pharmacol Ther Toxicol 1992: 30, 383-387.
2. Bartsch H, Caporaso N, Coda M, Kadlubar F, Malaveille C, Skipper P, Talaska G, Tannenbaum SR, Vinies P. Carcinogen haemoglobin adduct, urinary mutagenicity and metabolic phenotype in active and passive cigarette smokers, J Natl Canc Inst 1990: 82, 1825-1831.
3. Bartsch H, Malaveille C, Freisen M, Kadlubar FF, Vineis P. Black (air-cured) and blond (flue-cured) tobacco cancer risk IV: molecular dosimetry studies implicate aromatic amines as bladder carcinogens. Eur J Cancer 1993: 29A, 1199-1207.
4. Bechtel YC, Bonaiti-Pellie C, Poisson N, Magnette J, Bechtel PR. A population and family study of N-acetyltransferase using caffeine urinary metabolites. Clin Pharmacol Ther 1993: 54, 134-141.
5. Berthou F, Goasduff T, Lucas Drèano Y, Le Bot MH, Mènez JF. Interaction between two probes used for phenotyping cytochromes P4501A2 (caffeine) and P4502E1 (chlorzoxazone) in humans. Pharmacogentics 1995: 5, 72-79.
6. Birkett DJ, Miners JO, Attwood J. Secondary metabolism of theophylline biotransformation products in man-route of formation of 1-methyluric acid. Br J Clin Pharmacol 1983: 15, 117-119.
7. Blanchard J, Sawers SJA. The absolute bioavailability of caffeine in man. Eur J Clin Pharmacol 1983: 24, 93-98.
8. Bonati M, Lattini R, Galetti F, Young JF, Tognoni G, Garattini S. Caffeine disposition after oral doses. Clin Pharmacol Ther 1982: 32, 98-106.
9. Butler MA, Lang NP, Young JF, Caparoso, NE, Venies P, Hayes RB, Teitel CH, Massengill JP, Lawsen MF, Kadlubar FF. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 1992: 2, 116-127.
10. Callahan MM, Robertson RS, Branfman AR, McComish MF, Yesair DW. Comparison of caffeine metabolism in three nonsmoking populations after oral administration of radiolabeled caffeine. Drug Met Dispos 1993: 11, 211-217.
11. Campbell ME, Spielberg SP, Kalow W. A urinary metabolic ratio that reflects systemic caffeine clearance. Clin Pharmacol Ther 1987: 42, 157-165.
12. Carillo JA, Benitez J. Caffeine metabolism in a healthy Spanish population: N-acetylator phenotype and oxidation pathways. Clin Pharmacol Ther 1994: 55, 293-334.
13. Catteau A, Bechtel YC, Poisson N, Bechtel PR, Bonaïti-Pellie C. A population and family study of CYP1A2 using caffeine urinary metabolites. Eur J Clin Pharmacol 1995: 47, 423-430.
14. Denaro CP, Brown CR, Wilson M, Jacob III P, Benowitz NL. Dose dependence of caffeine metabolism with repeated dosing. Clin Pharmacol Ther 1990: 48, 277-285.
15. Evans WE, Relling MV, Petros WP, Meyer WH, Mirro J, Crom WR. Dextromethorphan and caffeine as a probes for simultaneous determination of debrisoquin-oxidation and N-acetylation phenotypes in children. Clin Pharmacol Ther 1989: 45, 568-573.
16. Führ U, Rost KL. Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva. Pharmacogenetics 1994: 4, 109-116.
17. Grant DM, Tang BK, Kalow W. Polymorphic N-acetylation of caffeine metabolite. Clin Pharmacol Ther 1983a: 33, 355-359.
18. Grant DM, Tang BK, Kalow W. Variability in caffeine metabolism. Clin Pharmacol Ther 1983b: 33, 591-602.
19. Grant DM, Tang BK, Kalow W. A simple test for acetylator phenotype using caffeine. Br J Clin Pharmacol 1984: 17, 459-464.
20. Grant DM, Tang BK, Campbell ME, Kalow W. Effect of allopurinol on caffeine disposition in man. Br J Clin Pharmacol 1986: 21, 454-458.
21. Grygiel JJ, Wing LMH, Farkas J, Birkett DJ. Effects of allopurinol on theophylline metabolism and clearance. Clin Pharmacol Ther 1979: 26, 660-667.
22. Gu L, Gonzalez FJ, Kalow W, Tang BK. Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1. Pharmacogenetics 1992: 2, 73-77.
23. Hardy BG, Lemieux C, Walker SE, Bartle WR. Interindividual variability in acetylation: characterization with caffeine. Clin Pharmacol Ther 1988: 44, 152-157.
24. Hildebrand M, Seiert W. Determination of acetylator phenotype in caucasions with caffeine. Eur J Clin Pharmacol 1989: 37, 525-526.
25. Houston JB. Drug metabolite kinetics. In: Rowland M, Tucker GT, eds. Pharmacokinetics: theory and methodology. Oxford: Pergamon Press, 1986: 131-162.
26. Jackson PR, Tucker GT, Lennard MS, Woods HF. Polymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices. Br J Clin Pharmacol 1986: 22, 541-550.
27. Jackson PR, Tucker GT, Woods HF. Testing for bimodality in frequency distributions of data suggesting polymorphism of drug metabolism-histograms and probit plots. Br J Clin Pharmacol 1989a: 28, 647-653.
28. Jackson PR, Tucker GT, Woods HF. Testing for bimodality in frequency distribution of data suggesting polymorphism of drug metabolism-hypothesis testing. Br J Clin Pharmacol 1989b: 28, 655-662.
29. Jost G, Wahlländer A, Von Mandech U, Preisig R. Overnight salivary caffeine clearance: A liver function test suitable for routine use. Hepatol 1987: 7, 338-344.
30. Kadlubar FF, Talaska G, Butler MA, Teitel CH, Masseng JP, Lang NP. Determination of carcinogenic arylamine N-oxidation phenotype in human by analysis of caffeine urinary metabolites. Prog Clin Biol Res 1990: 340B, 107-114.
31. Kadlubar FF. Biochemical individuality and its implications for drug and carcinogen metabolism: Recent insights from aceyltransferase and cytochrome P4501A2 phenotyping and genotyping in humans. Drug Metab Rev 1994: 26, 37-46.
32. Kalow W, Tang B-K. Caffeine as a metabolic probe: exploration of the enzyme-inducing effect of cigarette smoking. Clin Pharmacol Ther 1991a: 49, 44-48.
33. Kalow W, Tang B-K. Use of caffeine metabolic ratios to explore CYP1A2 and xanthine oxidase activities. Clin Pharmacol Ther 1991b: 50, 508-519.
34. Kalow W, Tang B-K. The use of caffeine for enzyme assays: a critical appraisal. Clin Pharmacol Ther 1995: 53, 503-514.
35. Kamimori GH, Lugo SI, Pentar DM, Chamberlin AC, Brunhart GE, Brunhart AE, Eddington ND. Dose dependent caffeine pharmacokinetics during severe sleep deprivation in humans. Int J Clin Pharmacol Therap 1995: 32, 182-186.
36. Kilbane AJ, Sibart LK, Manis M, Beitins IZ, Weber WW. Human N-acetylation genotype determination with urinary caffeine metabolites. Clin Pharmacol Ther 1990: 47, 470-477.
37. Lang NP, Butler MA, Massengill J, Lawson M, Stotts R, Hauer-Jensen M, Kadlubar FF. Rapid metabolic phenotypes for acetyltransferase and cytochrome P4501A2 and putative exposure to food-borne heterocyclic amines increase the risk for colorectal cancer or polyps. Cancer Epidemiol Biomarkers Preven 1994, 3, 675-682.
38. Lelo A, Birkett DJ, Robinson RA, Miners JO. Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. Br J Clin Pharmacol 1986a: 22, 177-182.
39. Lelo A, Miners JO, Robson RA, Birkett DJ. Quantitative assessment of caffeine partial clearances in man. Br J Clin Pharmacol 1986b: 22, 183-186.
40. Lelo A, Kjellen G, Birkett DJ, Miners JO. Paraxanthine metabolism in humans: determination of metabolic partial clearances and effect of allopurinol and cimetidine. J Pharmacol Exp Ther 1989: 248, 315-319.
41. Lewis FW, Rector Jr. WG. Caffeine clearance in cirrhosis: The value of simplified determinations of liver metabolic capacity. J Hepatology 1992: 14, 157-162.
42. Nakajima M, Yokoi T, Mizutani M, Shin S, Kadlubar FF, Kamataki T. Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites - absence of mutation prescribing the phenotype in the CYP1A2 gene. Cancer Epidemiol Biomakers Preven 1994: 3, 413-421.
43. Notarianni LJ, Oliver SE, Dobrocky P, Bennett PN, Silverman BW. Caffeine as a metabolic probe: A comparison of the metabolic ratios used to assess CYP1A2 activity. Br J Clin Pharmacol 1995: 39, 65-69.
44. Numerical Algorithm Group. NAG Fortran Library Manual, Vol. 6, Oxford, 1988.
45. Pang KS. Kinetics of sequential metabolism: Contribution of parallel, primary metabolic pathways to the formation of common, secondary metabolite. Drug Metab Dispos 1995: 23, 166-177.
46. Price-Evans DA. Genetic factors in drug therapy: clinical and molecular pharmacogenetics. Cambridge: Cambridge University Press, 1993: 211-285.
47. Prior WAJ. GHOST User Manual. Version 8, AEA Technology, Calham Laboratory, Abingdon, 1991.
48. Relling MV, Lin J-S, Ayers GD, Evans WE. Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities. Clin Pharmacol Ther 1992: 52, 643-658.
49. Renner E, Wietholtz H, Huuiienin PH, Wietholtz A, Preisig R. Coffein-ein ubiquitärer Indikator der Leberfunktion. Schweiz Med Wschr 1983: 113, 1074-1081.
50. Rieder MJ, Shear NH, Kanee A, Tang BK, Spielberg SP. Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reaction. Clin Pharmacol Ther 1991: 49, 13-17.
51. Rost KL, Roots I. Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolite ratios: coincidence with plasma clearance and breath test. Clin Pharmacol Ther 1994: 54, 402-411.
52. Shimada T, Yamazaki H, Mimura M, Inui K, Guengerich FP. Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994: 270, 414-423.
53. St-Pierre MV, Xu X, Pang KS. Primary, secondary and tertiary metabolite kinetics. J Pharmacokin Biopharm 1988: 16, 493-527.
54. Spigelman AD, Farmer KCR, Oliver S, Nugent KP, Bennett PN, Notarianni LJ, Bobrocky P, Phillips RKS. Caffeine phenotyping of cytochrome P4501A2, N-acetyltransferase, and xanthine oxidase in patients with familial adenomatous polyposis. Gut 1995: 36, 251-254.
55. Tanaka E, Ishikawa A, Yamamoto Y, Osada A, Tsuki K, Fukao K, Misawa, Iwasaki Y. A simple useful method for the determination of hepatic function in patients with liver cirrhosis using caffeine and its three major dimethylmetabolites. Int J Clin Pharmacol Ther Toxicol 1992: 30, 336-341.
56. Tang BK, Kadar D, Kalow W. An alternative test for acetylator phenotyping with caffeine. Clin Pharmacol Ther 1987: 42, 509-513.
57. Tang BK, Kadar D, Qian L, Iriah J, Yip J, Kalow W. Caffeine as a metabolic probe: validation of its use for acetylator phenotyping. Clin Pharmacol Ther 1991: 49, 648-657.
58. Tang BK, Zhou Y, Kadar D, Kalow W. Caffeine as a probe for CYP1A2 activity: potential influence of renal factors on urinary phenotypic trait measurements. Pharmacogenetics 1994: 4, 117-124.
59. Tang-Liu DD-S, Williams RL, Riegelman S. Nonlinear theophylline elimination. J Pharmacol Exp Ther 1982: 31, 358-365.
60. Tang-Liu DD-S, Tozer TN, Riegelman S. Dependence of renal clearance on urine flow: A mathematical model and its application. J Pharm Sci 1983a: 72, 154-158.
61. Tang-Liu DD-S, Williams RL, Riegelman, S. Disposition of caffeine and its metabolites in man. J Pharmacol Exp Ther 1983b: 224, 180-185.
62. Tassaneeyakul W, Mohamed Z, Birkett DJ, McManus ME, Veronese ME, Tukey RH, Quattrochi J, Gonzalez F, Miners JO. Caffeine as a probe for human cytochromes P450: validation using cDNA-expression, immunoinhibition and microsomal kinetic and inhibitor techniques. Pharmacogenetics 1992: 2, 173-183.
63. Tassaneeyakul W, Birkett DJ, McManus ME, Tassaneeyakul W, Veronese ME, Andersson T, Tukey RH, Miners JO. Caffeine metabolism by human hepatic cytochromes P450: contributions of 1A2, 2E1 and 3A isoforms. Biochem Pharmacol 1994: 47, 1767-1776.
64. Tucker GT, Rostami-Hodjegan A, Jackson PR. The determination of drug metabolising status in vivo: pharmacokinetic and statistical issues. In: Pacifici GM, Fracchia GN. Advances in drug metabolism in man. Brussels, Official Publications of the EC, 1995: 35-56.
65. Ulrich D, Compognone D, Münch B, Brandes A, Hille H, Bircher J. Urinary caffeine metabolites in man, age-dependent changes and pattern in various clinical situations. Eur J Clin Pharmacol 1992: 43, 167-172.
66. Vistisen K, Poulsen HE, Loft S. Foreign compound metabolism in man measured from metabolites of dietary caffeine. Carcinogenesis 1992: 13, 1561-1568.
67. Wahlländer A, Mohr S, Paumgartner G. Assessment of hepatic function: comparison of caffeine clearance in serum and saliva during the day and at night. J Hepatology 1990: 10, 129-137.
68. Wilkinson GR, Shand DG. A physiological approach to hepatic drug clearance. Clin Pharmacol Ther 1975: 18, 377-390.
69. Yokoi T, Sawada M, Kamataki T. Polymorphic drug metabolism: studies with recombinant Chinese hamster cells and analyses in human populations. Pharmacogenetics 1995: 5, S65-S69.